license

Asahi Kasei Life Science Licenses Novel ADC Technology From The Noguchi Institute

Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute.

News • Pharma

Cyprumed and MSD Enter Licensing Agreement for Oral Peptide Therapeutics

MSD receives a non-exclusive license for Cyprumed's drug delivery technology for developing oral peptide therapeutics.

News

ECI Group Secures First 150kta Copolymer License

ECI Group recently announced the signing of a licensing agreement with Shaanxi Yanchang China Coal Yulin Energy & Chemical Co., Ltd. (YECC) to deliver a 150kta copolymer plant project using ECI Group’s proprietary hybrid reactor technology.

News

Air Liquide Takes MCC Butene License

News

NatureWorks Picks Plaxica’s D-lactic Acid Process

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

INOSIM GmbH

Predictive Simulation in Pharma Production

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.